This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Oct 1;14(5):295-7.

doi: 10.2165/11640510-000000000-00000.

Understanding the value of information from pediatric clinical research

Wendy J Ungar¹

Affiliations

PMID: 22897161
DOI: 10.2165/11640510-000000000-00000

Comment

Understanding the value of information from pediatric clinical research

Wendy J Ungar. Paediatr Drugs. 2012.

. 2012 Oct 1;14(5):295-7.

doi: 10.2165/11640510-000000000-00000.

Author

Wendy J Ungar¹

Affiliation

¹ Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada. wendy.ungar@sickkids.ca

PMID: 22897161
DOI: 10.2165/11640510-000000000-00000

No abstract available

PubMed Disclaimer

Comment on

Measuring the patient health, societal and economic benefits of US pediatric therapeutics legislation.
Vernon JA, Shortenhaus SH, Mayer MH, Allen AJ, Golec JH. Vernon JA, et al. Paediatr Drugs. 2012 Oct 1;14(5):283-94. doi: 10.2165/11633590-000000000-00000. Paediatr Drugs. 2012. PMID: 22775493

Similar articles

Pharmaceutical industry financial performance.
Goodman M. Goodman M. Nat Rev Drug Discov. 2009 Dec;8(12):927-8. doi: 10.1038/nrd3049. Nat Rev Drug Discov. 2009. PMID: 19949398 No abstract available.
Goodbye Columbus! New NRDOs forego discovery.
Thiel KA. Thiel KA. Nat Biotechnol. 2004 Sep;22(9):1087-92. doi: 10.1038/nbt0904-1087. Nat Biotechnol. 2004. PMID: 15340473 No abstract available.
Cost-effectiveness data on biologics needed.
Sheridan C, Katsnelson A. Sheridan C, et al. Nat Biotechnol. 2005 Mar;23(3):272-3. doi: 10.1038/nbt0305-272. Nat Biotechnol. 2005. PMID: 15765069 No abstract available.
Pharmaceutical and other commercial uses of the dog model.
Ikeda-Douglas CJ, de Rivera C, Milgram NW. Ikeda-Douglas CJ, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Mar;29(3):355-60. doi: 10.1016/j.pnpbp.2004.12.001. Prog Neuropsychopharmacol Biol Psychiatry. 2005. PMID: 15795043 Review. No abstract available.
R&D technology investments: misguided and expensive or a better way to discover medicines?
Schmid EF, Smith DA. Schmid EF, et al. Drug Discov Today. 2006 Sep;11(17-18):775-84. doi: 10.1016/j.drudis.2006.07.007. Drug Discov Today. 2006. PMID: 16935744 Review.

See all similar articles

References

1. Br J Clin Pharmacol. 2002 Dec;54(6):665-70 - PubMed
1. Child Adolesc Psychiatry Ment Health. 2008 Dec 08;2(1):37 - PubMed
1. CMAJ. 2005 Apr 26;172(9):1159-60 - PubMed
1. Paediatr Drugs. 2012 Oct 1;14(5):283-94 - PubMed
1. Ital J Pediatr. 2011 Jan 19;37:7 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer
Medical
- MedlinePlus Health Information